Eli Lilly reported a record quarter driven by strong sales of its weight-loss injection, Zepbound. The company raised its 2026 revenue outlook for the third time this year, now expecting between $91 billion and $92 billion. This reflects the growing dominance of Zepbound in the U.S. prescription weight-loss drug market. Lilly's shares rose 4.6% in premarket trading following the announcement.
Eli Lilly's stock price on Pluang is USD 1,340.00 as of Oct 29, 2026 18:02 WIB, showing a 3.97% increase in one day. The stock's market capitalization stands at $1.15 trillion, reflecting its significant size in the health sector. Most Pluang investors hold the stock for about 94 days, with 71% currently buying and 29% selling.
Eli Lilly reported a 39% revenue increase to $24.4 billion in Q3 2026, led by strong sales of Mounjaro and Zepbound. Earnings per share rose 16% to $7.22 on a reported basis, with the company raising its full-year revenue guidance to $91-$92 billion....
Eli Lilly will report its third-quarter earnings and revenue, expected to be boosted by strong sales of its obesity drug Zepbound and diabetes treatment Mounjaro. Investors are also watching the performance of Foundayo, an obesity pill launched in Ap...
A recent survey shows 16% of large employers are thinking about dropping coverage for GLP-1 weight-loss drugs due to high costs, up from 9% last year. This shift could reduce employer-paid prescriptions but may increase cash purchases by patients, af...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
